Molecular Partners Ag (MOLN) FCF Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly FCF Margin of 105.95% for Q1 2026, down 292.0% year-on-year from 55.18% in Q1 2025, and down 100.09% on a QoQ basis from 114276.0% in Q4 2025.
Molecular Partners Ag (MOLN) FCF Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported FCF Margin for 7 consecutive years, with 105.95% the latest figure, recorded in Q1 2026.
- Quarterly FCF Margin fell 292.0% year-over-year to 105.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1715826.76% (up 171582558.0% YoY) and the FY2025 annual result came in at 89450946.64%, down 8944974758.0% from the prior year.
- FCF Margin declined to 105.95% in Q1 2026 per MOLN's latest filing, from 114276.0% in the prior quarter.
- Over the last five years, FCF Margin for MOLN reached as high as 4759693.98% in Q3 2024 and fell as low as 2091687491.94% in Q2 2024.
- A 5-year average of 122681223.55% and a median of 0.0% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 2000000000 bps — and 2025, when it jumped 2000000000 bps.
- Year by year, FCF Margin stood at 78.27% in 2022, then plunged by 1182 bps to 846.66% in 2023, then soared by 100 bps to 1.21% in 2024, then soared by 9470837 bps to 114276.0% in 2025, then plunged by 100 bps to 105.95% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 105.95%, 114276.0%, and 245715.81% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -105.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -105.95% |
| Dec 31, 2025 | 114,276.00% |
| Sep 30, 2025 | 245,715.81% |
| Jun 30, 2025 | -171,042.14% |
| Mar 31, 2025 | -103.04% |
| Dec 31, 2024 | 1.21% |
| Sep 30, 2024 | 4,759,693.98% |
| Jun 30, 2024 | -2,091,687,491.94% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | -846.66% |
| Sep 30, 2023 | 1,164,787.88% |
| Jun 30, 2023 | -7,138.20% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 78.27% |
| Sep 30, 2022 | -6.40% |
| Jun 30, 2022 | 1,286.35% |
| Mar 31, 2022 | 94.46% |
| Dec 31, 2021 | -942.07% |
| Sep 30, 2021 | 1,476,056.04% |
| Jun 30, 2021 | 5.34% |